Transcriptomic Analysis of Lacrimal Glands in a Sjogren’s Disease Animal Model Reveals Key Molecular Factors and Altered Biological Processes Associated with Glandular Inflammation and Dysfunction - Takeaways - MDSpire

Transcriptomic Analysis of Lacrimal Glands in a Sjogren’s Disease Animal Model Reveals Key Molecular Factors and Altered Biological Processes Associated with Glandular Inflammation and Dysfunction

  • By

  • Danny Toribio

  • Junji Morokuma

  • Albert Tai

  • Driss Zoukhri

  • March 13, 2026

  • 0 min

Share

  • 1

    Sjogren’s disease leads to chronic inflammation of lacrimal glands, resulting in aqueous-deficient dry eye disease due to impaired tear secretion.

  • 2

    Transcriptomic analysis revealed increased differential gene expression correlating with the progression of dacryoadenitis in a SjD mouse model.

  • 3

    Key pathways identified were related to immune responses, highlighting the role of cytokines and transcription factors in glandular inflammation.

  • 4

    Biological processes affected included lymphocyte migration and lipid metabolism, indicating significant alterations in glandular function.

  • 5

    Targeting dysregulated molecules and pathways may provide new therapeutic strategies for treating chronic lacrimal gland inflammation.

Original Source(s)

Transcriptomic Analysis of Lacrimal Glands in a Sjogren’s Disease Animal Model Reveals Key Molecular Factors and Altered Biological Processes Associated with Glandular Inflammation and Dysfunction

  • by Danny Toribio, Junji Morokuma, Albert Tai, Driss Zoukhri

  • March 13, 2026

Related Content

Red Eye, Global Challenge

Narrative review calls for clearer guidance on noninfectious conjunctival hyperemia

  • March 18, 2026

  • 2 min
The Relationship of Tear Film Instability and Higher-Order Aberrations to Refractive Variability

Jade Coats, OD, discusses the effects of higher-order abberations on refractions and what to do about them.

Japan Debuts Novel Dry Eye Therapy

Senju Pharmaceutical launches the first TRPV1 antagonist for dry eye in Japan

  • April 30, 2026

  • 3 min